Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
darlifarnib + cabozantinib
- Development stage
- Phase 1
- Lead developer
- Kura Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Darlifarnib + cabozantinib is an investigational combination therapy consisting of darlifarnib (formerly KO-2806), an oral, next-generation farnesyltransferase inhibitor (FTI), and cabozantinib (Cabometyx), a marketed multi-targeted receptor tyrosine kinase inhibitor. Developed by Kura Oncology, darlifarnib is designed to enhance the antitumor and antiangiogenic effects of cabozantinib and overcome adaptive resistance to VEGFR tyrosine kinase inhibitors (TKIs). Mechanistically, darlifarnib inhibits farnesyltransferase, which blocks the farnesylation of RHEB, thereby preventing the hyperactivation of the mTORC1 signaling pathway in endothelial and tumor cells. This combination is being evaluated in the Phase 1a/1b FIT-001 trial (NCT06026410) for the treatment of advanced renal cell carcinoma (RCC), particularly clear cell RCC (ccRCC), in both cabozantinib-naive and cabozantinib-pretreated patients.
- Other names
- KO-2806 + CabometyxKO-2806 + cabozantinibdarlifarnib + Cabometyxdarlifarnib + cabozantinib
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)RET (Rearranged during transfection receptor tyrosine kinase)RHEB (GTP-binding protein Rheb)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)MET (Mesenchymal-epithelial transition factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FNTB (Farnesyltransferase beta subunit)FNTA (Protein farnesyltransferase/geranylgeranyltransferase Type-1 subunit alpha)AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on darlifarnib + cabozantinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on darlifarnib + cabozantinib.